|
1.
|
|
6 p, 870.5 KB |
Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy : differences according to KRAS G12C vs. non-G12C
/
Notario, Lucía (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cucurull, Marc (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cerdà, Gabriela (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sanz, Carolina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Muñoz-Mármol, Ana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Hernández, Ainhoa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Domènech, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Costa, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mate, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Esteve, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Saigí, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who were treated with immunotherapy-based regimens and we evaluated the clinical outcomes according to PD-L1 expression and the type of KRAS mutation. [...]
2023 -  10.3389/fonc.2023.1239000
Frontiers in Oncology, Vol. 13 (october 2023)
|
|
|
2.
|
|
12 p, 6.9 MB |
EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
/
Chalela, Roberto (Hospital del Mar (Barcelona, Catalunya)) ;
Bellosillo Paricio, Beatriz (Hospital del Mar (Barcelona, Catalunya)) ;
Curull Serrano, Víctor (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Longarón, Raquel (Hospital del Mar (Barcelona, Catalunya)) ;
Pascual-Guardia, Sergi (Hospital del Mar (Barcelona, Catalunya)) ;
Badenes-Bonet, Diana (Hospital del Mar (Barcelona, Catalunya)) ;
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
Sánchez-Font, Albert (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Pijuan, Lara (Hospital del Mar (Barcelona, Catalunya)) ;
Gea Guiral, Joaquim (Hospital del Mar (Barcelona, Catalunya))
Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung. [...]
2019 - 10.3390/jcm8040529
Journal of clinical medicine, Vol. 8 (april 2019)
|
|
|
3.
|
|
6 p, 1.0 MB |
EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
/
Chalela, Roberto (Institut Hospital del Mar d'Investigacions Mèdiques) ;
González-García, Jose Gregorio (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Khilzi, Karys (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Curull Serrano, Víctor (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Sánchez-Font, Albert (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Longarón, Raquel (Hospital del Mar (Barcelona, Catalunya)) ;
Rodrigo-Calvo, María Teresa (Hospital del Mar (Barcelona, Catalunya)) ;
Martín-Ontiyuelo, Clara (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Gea Guiral, Joaquim (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Bellosillo Paricio, Beatriz (Institut Hospital del Mar d'Investigacions Mèdiques)
The acquisition of driver mutations in non-tumoral cells appears to be very important during the carcinogenesis of adenocarcinoma (ADC). Recent studies suggest that cancer-related mutations may not necessarily be present only in malignant cells, but also in histologically "healthy cells". [...]
2021 - 10.3389/pore.2021.598292
Pathology and Oncology Research, Vol. 27 (march 2021)
|
|
|
4.
|
|
8 p, 712.6 KB |
Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
/
Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ;
Portnoy, D. C. (The West Clinic, Memphis, USA) ;
Obermannová, R. (Masarykuv Onkologicky Ustav, Brno, Czech Republic) ;
Bodoky, G. (St László Hospital (Hongria)) ;
Prausová, J. (Fakultni Nemocnice v MOTOLE, Prague, Czech Republic) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Cohn, A. L. (Rocky Mountain Cancer Center, LLP, Denver, USA) ;
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Yamazaki, K. (Shizuoka Cancer Center, Shizuoka, Japan) ;
Lonardi, Sara (Istituto Oncologico Veneto-IRCCS, Padova, Italy) ;
Muro, K. (Aichi Cancer Center Hospital) ;
Kim, T. W. (Asan Medical Center, University of Ulsan, Seoul, Republic of Korea) ;
Yamaguchi, K. (The Cancer Institute Hospital of JFCR, Tokyo, Japan) ;
Grothey, A. (Mayo Clinic, Phoenix, USA) ;
O'Connor, J. (Instituto Alexander Fleming (Buenos Aires, Argentina)) ;
Taieb, Julien (Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France) ;
Wijayawardana, S. R. (Eli Lilly and Company, Indianapolis, USA) ;
Hozak, Rebecca R (Eli Lilly and Company, Indianapolis, USA) ;
Nasroulah, F. (Eli Lilly and Company, Buenos Aires, Argentina) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Vall d'Hebron Institut d'Oncologia
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0. 84, 95% CI 0. 73-0. [...]
2018 - 10.1093/annonc/mdy461
Annals of oncology, Vol. 30 (october 2018) , p. 124-131
|
|
|
5.
|
|
9 p, 435.9 KB |
Prediction of overall survival in stage II and III colon cancer beyond TNM system : a retrospective, pooled biomarker study
/
Dienstmann, Rodrigo. (Hospital Universitari Vall d'Hebron) ;
Mason, M. J. (Computational Oncology, Sage Bionetworks, Seattle, USA) ;
Sinicrope, F. A. (Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA) ;
Phipps, A. I. (Fred Hutchinson Cancer Research Center, Seattle, USA) ;
Tejpar, Sabine (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Nesbakken, A. (Oslo University Hospital (Oslo, Noruega)) ;
Danielsen, S. A. (Oslo University Hospital (Oslo, Noruega)) ;
Sveen, A. (Oslo University Hospital (Oslo, Noruega)) ;
Buchanan, Daniel D (The University of Melbourne) ;
Clendenning, M. (The University of Melbourne) ;
Rosty, C. (The University of Melbourne) ;
Bot, Brian M (Computational Oncology, Sage Bionetworks, Seattle, USA) ;
Alberts, S. R. (Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA) ;
Milburn Jessup, J. (National Cancer Institute (Rockville, Estats Units d'Amèrica)) ;
Lothe, R. A. (Oslo University Hospital (Oslo, Noruega)) ;
Delorenzi, Mauro (SIB Swiss Institute Bioinformatics, Lausanne, Switzerland) ;
Newcomb, P. A. (Fred Hutchinson Cancer Research Center, Seattle, USA) ;
Sargent, D. (Mayo Clinic, Rochester, USA) ;
Guinney, J. (Computational Oncology, Sage Bionetworks, Seattle, USA) ;
Universitat Autònoma de Barcelona
TNM staging alone does not accurately predict outcome in colon cancer (CC) patients who may be eligible for adjuvant chemotherapy. It is unknown to what extent the molecular markers microsatellite instability (MSI) and mutations in BRAF or KRAS improve prognostic estimation in multivariable models that include detailed clinicopathological annotation. [...]
2017 - 10.1093/annonc/mdx052
Annals of oncology, Vol. 28 (february 2017) , p. 1023-1031
|
|
|
6.
|
|
9 p, 306.4 KB |
Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
/
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Hendlisz, A. (Institut Jules Bordet (Belgium)) ;
Delaunoit, T. (Centres Hospitaliers Jolimont (Belgium)) ;
Sastre Valera, Javier (Hospital Clínico San Carlos (Madrid)) ;
Cervantes, Andrés (Instituto de Investigación Sanitaria INCLIVA (València, Comunitat Valenciana)) ;
Varea, R. (Eli Lilly and Company (Spain)) ;
Chao, G. (Eli Lilly and Company (USA)) ;
Wallin, J. (Eli Lilly and Company (Suècia)) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC). [...]
2016 - 10.1038/bjc.2015.480
British Journal of Cancer, Vol. 114 (February 2016) , p. 372-380
|
|
|
7.
|
|
6 p, 225.1 KB |
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer : results of the EXPERT-C trial
/
Sclafani, Francesco (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Chau, Ian (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Cunningham, David (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Peckitt, C. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Lampis, Andrea (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ;
Hahne, Jens Claus (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ;
Braconi, Chiara (The Institute of Cancer Research. Division of Cancer Therapeutics (UK)) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Glimelius, B. (University of Uppsala. Department of Immunology, Genetics and Pathology (Sweden)) ;
Cervantes, Andrés (Universitat de València. Departament d'Hematologia i Oncologia Mèdica) ;
Begum, Ruwaida (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
González De Castro, David (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Hulkki Wilson, Sanna (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Tait, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Brown, Gina (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Oates, J. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ;
Valeri, Nicola (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ;
Universitat Autònoma de Barcelona
Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. [...]
2015 - 10.1093/annonc/mdv285
Annals of oncology, Vol. 26, Issue 9 (September 2015) , p. 1936-1941
|
|
|
8.
|
|
8 p, 207.5 KB |
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS -mutated metastatic colorectal cancer
/
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Cervantes, Andrés (Universitat de València. Biomedical Research Institute) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Roselló, Susana (Universitat de València. Biomedical Research Institute) ;
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Tejpar, Sabine (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Prenen, H. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Martinelli, E. (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Troiani, T. (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Laffranchi, B. (Merck Serono SA) ;
Jego, V (Merck Serono SA) ;
von Richter, O. (Merck KGaA) ;
Ciardiello, Fortunato (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Universitat Autònoma de Barcelona
The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. [...]
2015 - 10.1038/bjc.2015.144
British Journal of Cancer, Vol. 112 (June 2015) , p. 1874-1881
|
|
|
9.
|
|
12 p, 5.3 MB |
Methylation of MGMT and ADAMTS14 in normal colon mucosa : biomarkers of a field defect for cancerization preferentially targeting elder African-Americans
/
Alonso, Sergio (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Dai, Yuichi (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Yamashita, Kentaro (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Horiuchi, Shina (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Dai, Tomoko (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Matsunaga, Akihiro (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Sánchez Muñoz, Rosa (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Bilbao Sieyro, Cristina (Instituto Canario de Investigación del Cáncer) ;
Díaz Chico, Juan Carlos (Instituto Canario de Investigación del Cáncer) ;
Chernov, Andrei V. (Sanford Burnham Prebys Medical Discovery Institute (Califòrnia)) ;
Strongin, Alex Y. (Sanford Burnham Prebys Medical Discovery Institute (Califòrnia)) ;
Perucho, Manuel (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer)
Somatic hypermethylation of the O6-methylguanine-DNA methyltransferase gene (MGMT) was previously associated with G > A transition mutations in KRAS and TP53 in colorectal cancer (CRC). We tested the association of MGMT methylation with G > A mutations in KRAS and TP53 in 261 CRCs. [...]
2015 - 10.18632/oncotarget.2852
Oncotarget, Vol. 6 Núm. 5 (february 2015)
|
|
|
10.
|
|
27 p, 8.4 MB |
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model
/
Álamo, Patricia (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Gallardo, Alberto (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Di Nicolantonio, Federica (Università degli studi di Torino. Dipartimento di Oncologia) ;
Pavón Ribas, Miguel Ángel (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Casanova Rigat, Isolda (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Trias Folch, Manuel (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Mangues, Ma Antonia (Institut d'Investigació Biomèdica Sant Pau) ;
López Pousa, Antonio (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Vázquez Gómez, Esther (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Bardelli, Alberto (Università degli studi di Torino. Dipartimento di Oncologia) ;
Céspedes, María Virtudes (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Mangues, Ramon 1957- (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina)
Although all KRas (protein that in humans is encoded by the KRas gene) point mutants are considered to have a similar prognostic capacity, their transformation and tumorigenic capacities vary widely. [...]
2015 - 10.1096/fj.14-262303
The FASEB journal, Vol. 29 Issue 2 (Feb. 2015) , p. 464-476
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
